[1]代宇婕,廖凌瑶,邱伊波,等.雌激素受体α36介导雌激素促进甲状腺乳头状癌细胞增殖的分子机制[J].第三军医大学学报,2017,39(24):2380-2384.
 DAI Yujie,LIAO Lingyao,QIU Yibo,et al.Molecular mechanism of estrogen receptor alpha-36 in 17β-estradiol-promoted proliferation in human papillary thyroid carcinoma cells[J].J Third Mil Med Univ,2017,39(24):2380-2384.
点击复制

雌激素受体α36介导雌激素促进甲状腺乳头状癌细胞增殖的分子机制(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
39卷
期数:
2017年第24期
页码:
2380-2384
栏目:
基础医学
出版日期:
2017-12-30

文章信息/Info

Title:
Molecular mechanism of estrogen receptor alpha-36 in 17β-estradiol-promoted proliferation in human papillary thyroid carcinoma cells
作者:
代宇婕廖凌瑶邱伊波刘智敏
重庆医科大学分子医学与肿瘤研究中心
Author(s):
DAI Yujie LIAO Lingyao QIU Yibo LIU Zhimin

Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, 400016, China

关键词:
雌激素受体&alpha36雌激素甲状腺乳头状癌ERK/AKT
Keywords:
estrogen receptor alpha-36 estrogen papillary thyroid carcinoma ERK/AKT
分类号:
Q347.913; R730.23; R736.1
文献标志码:
A
摘要:

目的    研究雌激素受体α36 (estrogen receptor alpha-36,ERα36)介导雌激素促进甲状腺乳头状癌 (papillary thyroid carcinoma, PTC) 细胞增殖的分子机制及相关信号通路。方法     采用免疫组化(S-P)检测ERα36在34例人PTC组织标本及其21例配对癌旁组织标本中的表达;梯度浓度E2(0、10-7、10-8、10-9 mol/L)处理PTC细胞株K1和BCPAP后,Western blot检测两种细胞株中ERα36的表达;10-8 mol/L E2处理后,Western blot检测两种细胞株ERK1/2和AKT磷酸化水平的变化,以及ERα36siRNA对其的抑制作用;梯度浓度的E2处理BCPAP细胞后,MTT法检测细胞增殖和ERα36-siRNA对增殖的抑制作用。结果     在人PTC组织中ERα36的阳性表达率为82.4%,明显高于癌旁组织(P<0.05)。PTC细胞株K-1和BCPAP均表达ERα36;10-8 mol/L E2处理细胞后,ERα36的表达增高,且呈时间依赖性。E2能促进BCPAP和K-1细胞ERK1/2和AKT蛋白磷酸化水平增高,且处理15 min 时BCPAP细胞最明显,10 min时K-1细胞最明显,而ERα36-siRNA能抑制E2的诱导效果;E2促进BAPAP细胞增殖,ERα36-siRNA则抑制E2的诱导效果。结论     ERα36通过ERK/AKT途径介导雌激素促进PTC细胞增殖。

Abstract:

Objective      To determine the effect of estrogen receptor-α36 (ERα36) on 17β-estradiol (E2)-promoted proliferation in papillary thyroid carcinoma (PTC) cells, and investigate the underlying mechanisms possibly involved. Methods    ERα36 protein expression was analyzed in 34 PTC tissue samples and 21 matched paracancerous tissues by immunohistochemical assay (S-P). Protein level of ERα36 in PTC cell lines BCPAP and K-1 in presence  and absence of E2 (10-7, 10-8 and 10-9 mol/L) was detected by Western blotting. The levels of phosphorylated ERK1/2 and AKT were analyzed in the BCPAP and K-1 cells with 10-8 mol/L E2 treatment by Western blotting. The BCPAP and K-1 cells were assigned into control, E2, E2+scrambled siRNA, and E2+ERα36-siRNA groups. The effect of ERα36-siRNA on the expression of above proteins was tested by Western blotting. Proliferation of BCPAP cells after the treatment of gradient doses of E2 was measured by MTT assay, and the effect of ERα36-siRNA on the proliferation was also studied. Results    The positive rates of ERα36 were 82.4% in PTC tissues, which were significantly higher than those in adjacent normal tissues (P<0.05). Both BCPAP and K-1 cells expressed ERα36, and 10-8 mol/L E2 treatment enhanced the expression level in a time-dependent manner. E2 treatment also resulted in increases in the phosphorylation of ERK1/2 and AKT, and most significant increases were observed in 15 min after the treatment in the BCPAP cells and 10 min in the K-1 cells. However, ERα36-siRNA inhibited these above promotions. What’s more, E2 induced cell proliferation in the BCPAP cells, which was suppressed by ERα36-siRNA. Conclusion    ERα36 may medicate E2promoting proliferation of PTC cells through ERK/AKT pathway.

参考文献/References:

[1]DALAL V, KAUR M, BANSAL A. Papillary carcinoma thyroid with anastomosing channels: An unusual morphology[J]. J Lab Physicians, 2017, 9 (2): 140-142. DOI: 10.4103/0974-2727.199631.
[2]RAHBARI R, ZHANG L, KEBEBEW E. Thyroid cancer gender disparity[J]. Future Oncol, 2010, 6(11):1771-1779. DOI: 10.2217/fon.10.127.
[3]DERWAHL M, NICULA D. Estrogen and its role in thyroid cancer[J]. Endocr Relat Cancer, 2014, 21(5):T273-283. DOI: 10.1530/ERC-14-0053.
[4]PRZYBYLIK-MAZUREK E, HUBALEWSKA-DYDEJCZYK A, FEDOROWICZ A, et al. Factors connected with the female sex seem to play an important role in differentiated thyroid cancer[J]. Gynecol Endocrinol, 2012, 28(2):150-155. DOI: 10.3109/09513590.2011.563909.
[5]WANG Z, ZHANG X, SHEN P, et al. Identification, cloning, and expression of human estrogen receptoralpha36, a novel variant of human estrogen receptor-alpha66[J]. Biochem Biophys Res Commun, 2005, 336(4):1023-1027. DOI: 10.1016/j.bbrc.2005.08.226.
[6]CHAUDHRI R A, SCHWARTZ N, ELBARADIE K, et al. Role of ERα36 in membrane-associated signaling by estrogen[J]. Steroids, 2014, 81: 74-80. DOI: 10.1016/j.steroids.2013.10.020.
[7]唐萃, 杨磊, 王旎, 等. G 蛋白偶联雌激素受体1、表皮生长因子受体和趋化因子受体1 在甲状腺乳头状癌中的表达及意义[J]. 第三军医大学学报, 2014, 36(12):1317-1321.
TANG C, YANG L, WANG N, et al. Expression and significance of GPER1, EGFR and CXCR1 in papillary thyroid carcinoma [J]. J Third Mil Med Univ, 2014, 36(12):1317-1321.
[8]赵乐,唐萃,杨磊, 等. Caveolin-1、GPR30和 Vimentin 在甲状腺乳头状癌组织中的表达及意义[J]. 中国免疫学杂志, 2015, 31(11):1510-1514. DOI: 10.3969/j.issn.1000484X.2015.11.015.
ZHAO L, TANG C, YANG L, et al. Expression and significance of Caveolin-1, GPR30 and Vimentin in papillary thyroid carcinoma [J]. Chin J Immunol, 2015, 31(11):1510-1514. DOI: 10.3969/j.issn.1000484X.2015.11.015.
[9]LIN S L, YAN L Y, ZHANG X T, et al. ERalpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways[J]. PLoS ONE, 2010, 5(2):e9013. DOI: 10.1371/journal.pone.0009013.
[10]YIN L, ZHANG X T, BIAN X W, et al. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells[J]. PLoS ONE, 2014, 9(9):e107369. DOI: 10.1371/journal.pone.0107369.
[11]CHAUDHRI R A, OLIVARES-NAVARRETE R, CUENCA N, et al. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36)[J]. J Biol Chem, 2012, 287(10):7169-7181. DOI: 10.1074/jbc.M111.292946.

更新日期/Last Update: 2017-12-26